20 articles
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
A new Oxford tool using 5.6 million patient records shows serious statin muscle side effects are rare, yet 60% of eligible patients skip the drug.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
USC researchers unlocked a scalable supply of engineered immune-cell precursors that fight tumors and may revolutionize cancer immunotherapy.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Experimental PCAI compounds blocked over 90% of pancreatic cancer cell migration and triggered self-destruction by hyperactivating tumor growth pathways.
Scientists discover why identical cancer treatments work for some patients but fail for others, revealing hidden drug reservoirs in cells.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
